SCHEMBL9368102

SCHEMBL9368102

CC(C)=CCOc1ccccc1/C=C/C(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.63
NPC1 O15118 4/20 0.63
LMNA P02545 3/20 0.63
RAB9A P51151 3/20 0.63
BCHE P06276 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.57
ATM Q13315 1/20 0.57
MAOB P27338 3/20 0.52
ALOX5 P09917 1/20 0.52
CYP1A2 P05177 3/20 0.51
CYP2D6 P10635 3/20 0.51
CYP1A1 P04798 2/20 0.51
CYP1B1 Q16678 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
RECQL P46063 1/20 0.51
GPR55 Q9Y2T6 1/20 0.51
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9368112 1.00 MAPT (0.63) MAPTNPC1LMNARAB9ABCHE
SCHEMBL11584287 0.91 PTPN1 (0.60) MAPTNPC1LMNARAB9ABCHE
SCHEMBL11584290 0.91 PTPN1 (0.60) MAPTNPC1LMNARAB9ABCHE
SCHEMBL5599785 0.84 ABCG2 (0.59) MAPTNPC1LMNARAB9ABCHE
SCHEMBL11583551 0.84 LMNA (0.57) MAPTNPC1LMNARAB9ABCHE
SCHEMBL11583549 0.84 LMNA (0.57) MAPTNPC1LMNARAB9ABCHE
SCHEMBL7197170 0.83 MAPT (0.62) MAPTNPC1LMNARAB9ABCHE
SCHEMBL7197164 0.83 MAPT (0.62) MAPTNPC1LMNARAB9ABCHE
SCHEMBL8330993 0.83 MAPT (0.80) MAPTNPC1LMNARAB9ABCHE
SCHEMBL8330997 0.83 MAPT (0.80) MAPTNPC1LMNARAB9ABCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0412803-B1 Chalcone derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 1994-03-23 EP claimed
EP-0412803-A1 Chalcone derivatives TAISHO PHARMACEUTICAL CO. LTD (JP) 1991-02-13 EP claimed
EP-2810198-B1 ANTI-INVASIVE COMPOUNDS UNIV GENT (BE) 2023-07-12 EP disclosed
US-9290427-B2 Anti-invasive compounds UNIVERSITEIT GENT (BE) 2016-03-22 US disclosed
US-20150011620-A1 ANTI-INVASIVE COMPOUNDS UNIVERSITEIT GENT (BE) 2015-01-08 US disclosed
EP-2810198-A1 ANTI-INVASIVE COMPOUNDS Universiteit Gent (BE) 2014-12-10 EP disclosed
WO-2013113722-A1 ANTI-INVASIVE COMPOUNDS UNIVERSITEIT GENT (BE) 2013-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150011620-A1 ANTI-INVASIVE COMPOUNDS MMP3, MMP10, MIF MAPT 3571/4885NPC1 129/4885LMNA 1863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.